FLT4 and fibrosis: In contrast, inhibition of VEGFR-3 reduces kidney lymphangiogenesis, glomerulosclerosis, and tubulointerstitial fibrosis in a mouse model of diabetic kidney disease as well as fibrosis following UUO and ischemia-reperfusion [10].